Transparency Market Research Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Published Date 2015-01-23
82 Page Report
Buy Now
Request Sample
Press Release
Kidney Cancer Drugs Market Expected to Reach USD 4.5 Billion Globally in 2020 Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Kidney Cancer Drugs Market
REPORT DESCRIPTION
Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020
According to a new market report published by Transparency Market Research “Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, the global kidney cancer drugs market was valued at USD 2.6 billion in 2013 and is expected to reach USD 4.5 billion in 2020, growing at a CAGR of 6.6% from 2014 to 2020.
Kidney cancer or renal cell carcinoma (RCC) is one of the common urologic tumors accounting for around 3% of all human malignancies. The incidence rate of renal cell carcinoma has increased progressively in the recent decades. According to the American Cancer Society, about 61,500 newly diagnosed cases are expected to occur in the U.S. in 2015. Kidney cancer rates are expected to increase every year with reduction in physical activity, rise in obesity and smoking, etc., which leads to an unhealthy lifestyle and increased susceptibility to cancer. The global incidence of kidney cancer diagnosis has reportedly increased by 10% to 30% every decade since 1999. Thus, high incidence and prevalence rates of kidney cancer have helped this market to transform it into billion-dollar market.
Browse the full Kidney Cancer Drugs Market Report at : http://www.transparencymarketresearch.com/kidney-cancer-drugsmarket.html
The global kidney cancer drugs market has been segmented based on the major branded drugs generally prescribed and used for the treatment of various types of kidney cancer such as Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus) and Proleukin (Aldesleukin). In terms of revenue, Sutent accounted for the largest share of over 30% of the kidney cancer drugs market in 2013. However, the drug is expected to grow at a sluggish CAGR of 1.1% from 2012 to 2016 and a CAGR of 2.1% from 2016 to 2020. Sunitinib is a well-known drug and often used as the first-line
Transparency Market Research
2
Kidney Cancer Drugs Market
treatment for RCC. Sunitinib is among the most studied drugs in its class for multiple indications, as it targets multiple receptor tyrosine kinases (RTKs). However, the relatively high price of the drug has often been regarded as a serious drawback to the use of Sutent, although the drug has been considered the first-line treatment agent for RCC. Moreover, in terms of market growth Votrient is expected to witness the highest growth rate among all kidney cancer drugs during the forecast period. The drug is expected to witness a CAGR of 41.7% from 2012 to 2016 and a CAGR of 8.9% from 2016 to 2020. However, with the loss of patent exclusivity, generic drug variants would offer clinicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the kidney cancer drugs market to an extent. Hence, commercialization of novel molecules for treating diverse kidney cancers including renal cell carcinoma would govern the future market growth of the kidney cancer drugs market.
Get Free Sample Report Kidney Cancer Drugs Market : http://www.transparencymarketresearch.com/sample/sample.php? flag=S&rep_id=537
Potential pipeline drugs identified and expected to be launched during the forecast period from 2014 to 2020 include Dovitinib [(TKI258) (Novartis AG)], Opdivo [(Nivolumab) (Bristol-Myers Squibb)], AGS-003 (Argos Therapeutics, Inc.), Cabozantinib [(XL184) (Exelixis, Inc.)] and Keytruda [(Anti PD 1) (Merck & Co., Inc.)]. Successful clinical trial outcomes of these molecules such as improved efficacy, with shorter onset of action and fewer side effects as well as expected commercialization during the forecast period are predicted to stimulate the growth of kidney cancer drugs market in the near future.
Geographically, North America accounted for the largest revenue share of kidney cancer drugs in 2013 (over 45%). The fact that the U.S. is the largest pharmaceutical market globally, accounting for a share of 90% of the market in North America, substantiates the dominance of the region in the global market. The U.S. accounts for the highest share of the revenue for each drug used for the treatment of kidney cancer. Canada accounts for the remaining 10% market share in North America. This leading position of the North American region in the kidney cancer drugs market is due to the presence of one or more branded formulations that influence the market dynamics significantly. The region also continues to dominate the market due to the high prevalence of kidney cancer. Hence, North America is expected to witness an appreciable growth rate
Transparency Market Research
3
Kidney Cancer Drugs Market
throughout the forecast period from 2014 to 2020. Asia Pacific is expected to experience the highest growth rate (over 6%) owing to various factors such as growing elderly population and existence of a large population base susceptible to kidney cancer. Additionally, strong economic growth in countries such as China, Japan, New Zealand and Australia would contribute to the growth of the market in Asia Pacific.
Browse the full Kidney Cancer Drugs Market press release at : http://www.transparencymarketresearch.com/pressrelease/kidney-cancer-drugs-market.htm
The market exhibits intense competition among existing players, as currently the market for kidney cancer drugs is highly consolidated, comprising a few established pharmaceutical giants. Major market players include Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG and Pfizer, Inc. Pfizer, Inc. held the largest share of over 40% of the total kidney cancer drugs market in 2013. Product differentiation, safety, distribution networks and supply capabilities play a major role in determining the market position of the company and other market players.
The global kidney cancer drugs market is segmented as follows:
Kidney Cancer Drugs Market, by Major Branded Drugs
➢ Sutent (Sunitinib)
➢ Nexavar (Sorafenib)
➢ Afinitor (Everolimus)
Transparency Market Research
4
Kidney Cancer Drugs Market
➢ Votrient (Pazopanib)
➢ Inlyta (Axitinib)
➢ Avastin (Bevacizumab)
➢ Torisel (Temsirolimus)
➢ Proleukin (Aldesleukin)
Kidney Cancer Drugs Market, by Geography
➢ North America
➢ Europe
➢ Asia Pacific
➢ Rest of the World (RoW)
TABLE OF CONTENT
Transparency Market Research
5
Kidney Cancer Drugs Market
Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 Assumptions
Chapter 2 Executive Summary 2.1 Market Snapshot: Global Kidney Cancer Drugs Market 2.2 Comparative Analysis: Global Kidney Cancer Drugs Market, By Geography, 2013 and 2020 (Value %)
Chapter 3 Global Kidney Cancer Drugs Market Overview 3.1 Market Dynamics and Overview 3.2 Market Drivers 3.2.1 Rising Incidence of Kidney Cancer Expected to Boost Market Growth 3.2.2 Increasing Geriatric Population Likely to Fuel the Growth of Kidney Cancer Drugs Market 3.2.2.1.1 Global Percentage Change in the World’s Population by Age: 2010-2050 3.2.3 Approval of Novel Molecules is Expected to Drive Market Growth 3.3 Market Restraints 3.3.1 High Prices of Branded Cancer Drugs might Impede the Growth of the Market 3.3.2 Increasing Preference for Generic Drug Variants might Negatively Influence the Market Growth 3.4 Market Opportunities
Transparency Market Research
6
Kidney Cancer Drugs Market
3.4.1 Focusing on Emerging Markets 3.5 Event Impact Analysis 3.6 Regulatory Framework 3.7 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography 3.8 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)
Chapter 4 Global Kidney Cancer Drugs Market, by Major Branded Drugs 4.1 Overview 4.1.1 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 – 2020 (USD Million) 4.2 Sutent (Sunitinib) 4.2.1 Global Sutent (Sunitinib) Market Revenue, 2012 – 2020 (USD Million) 4.3 Nexavar (Sorafenib) 4.3.1 Global Nexavar (Sorafenib) Market Revenue, 2012 – 2020 (USD Million) 4.4 Afinitor (Everolimus) 4.4.1 Global Afinitor (Everolimus) Market Revenue, 2012 – 2020 (USD Million) 4.5 Votrient (Pazopanib) 4.5.1 Global Votrient (Pazopanib) Market Revenue, 2012 – 2020 (USD Million) 4.6 Inlyta (Axitinib) 4.6.1 Global Inlyta (Axitinib) Market Revenue, 2012 – 2020 (USD Million) 4.7 Avastin (Bevacizumab) 4.7.1 Global Avastin (Bevacizumab) Market Revenue, 2012 – 2020 (USD Million)
Transparency Market Research
7
Kidney Cancer Drugs Market
4.8 Torisel (Temsirolimus) 4.8.1 Global Torisel (Temsirolimus) Market Revenue, 2012 – 2020 (USD Million) 4.9 Proleukin (Aldesleukin) 4.9.1 Global Proleukin (Aldesleukin) Market Revenue, 2012 – 2020 (USD Million)
Chapter 5 Global Kidney Cancer Drugs Market, Pipeline Analysis 5.1 Overview 5.1.1 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2020 (USD Million) 5.2 Opdivo (Nivolumab) (Bristol-Myers Squibb) 5.2.1 Global Opdivo Market Revenue, 2015 – 2020 (USD Million) 5.3 Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.) 5.3.1 Global Keytruda Market Revenue, 2015 – 2020 (USD Million) 5.4 Cabozantinib (XL184) (Exelixis, Inc.) 5.4.1 Global Cabozantinib Market Revenue, 2017 – 2020 (USD Million) 5.5 AGS-003 (Argus Therapeutics, Inc.) 5.5.1 Global AGS-003 Market Revenue, 2017 – 2020 (USD Million) 5.6 Dovitinib (TK1258) [Novartis AG] 5.6.1 Global Dovitinib Market Revenue, 2018 – 2020 (USD Million)
Chapter 6 Global Kidney Cancer Drugs Market, by Geography 6.1 Overview
Transparency Market Research
8
Kidney Cancer Drugs Market
6.1.1 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million) 6.2 North America 6.2.1 North America Kidney Cancer Drugs Market Revenue, 2012–2020 (USD Million) 6.3 Europe 6.3.1 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million) 6.4 Asia Pacific 6.4.1 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million) 6.5 Rest of the World (RoW) 6.5.1 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
Chapter 7 Recommendations
Chapter 8 Company Profiles 8.1 Bayer AG 8.1.1 Company Overview 8.1.2 Financial Overview 8.1.3 Product Portfolio 8.1.4 Business Strategy 8.1.5 Recent Developments 8.2 F. Hoffmann-La Roche, Ltd. 8.2.1 Company Overview
Transparency Market Research
9
Kidney Cancer Drugs Market
8.2.2 Financial Overview 8.2.3 Product Portfolio 8.2.4 Business Strategy 8.2.5 Recent Developments 8.3 GlaxoSmithKline, plc 8.3.1 Company Overview 8.3.2 Financial Overview 8.3.3 Product Portfolio 8.3.4 Business Strategy 8.3.5 Recent Developments 8.4 Novartis AG 8.4.1 Company Overview 8.4.2 Financial Overview 8.4.3 Product Portfolio 8.4.4 Business Strategy 8.4.5 Recent Developments 8.5 Pfizer, Inc. 8.5.1 Company Overview 8.5.2 Financial Overview 8.5.3 Product Portfolio 8.5.4 Business Strategy
Transparency Market Research
10
Kidney Cancer Drugs Market
8.5.5 Recent Developments List of Figures
FIG. 1 Kidney Cancer Drugs: Market Segmentation FIG. 2 Global Kidney Cancer Drugs Market, by Major Branded Drugs, 2013 (USD Million) FIG. 3 Global Kidney Cancer Pipeline Drugs Market (USD Million) FIG. 4 Comparative Analysis: Global Kidney Cancer Drugs Market, by Geography, 2013 and 2020 (Value %) FIG. 5 Kidney Cancer Drugs Market, Drivers and Restraints FIG. 6 Global Percentage Change in the World’s Population by Age: 2010 - 2050 FIG. 7 Major Developments in Kidney Cancer Drugs Market FIG. 8 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography FIG. 9 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %) FIG. 10 Global Sutent (Sunitinib) Market Revenue, 2012 – 2020 (USD Million) FIG. 11 Global Nexavar (Sorafenib) Market Revenue, 2012 – 2020 (USD Million) FIG. 12 Global Afinitor (Everolimus) Market Revenue, 2012 – 2020 (USD Million) FIG. 13 Global Votrient (Pazopanib) Market Revenue, 2012 – 2020 (USD Million) FIG. 14 Global Inlyta (Axitinib) Market Revenue, 2012 – 2020 (USD Million) FIG. 15 Global Avastin (Bevacizumab) Market Revenue, 2012 – 2020 (USD Million) FIG. 16 Global Torisel (Temsirolimus) Market Revenue, 2012 – 2020 (USD Million) FIG. 17 Global Proleukin (Aldesleukin) Market Revenue, 2012 – 2020 (USD Million) FIG. 18 Global Opdivo Market Revenue, 2015 – 2020 (USD Million)
Transparency Market Research
11
Kidney Cancer Drugs Market
FIG. 19 Global Keytruda Market Revenue, 2015 – 2020 (USD Million) FIG. 20 Global Cabozantinib Market Revenue, 2017 – 2020 (USD Million) FIG. 21 Global AGS-003 Market Revenue, 2017 – 2020 (USD Million) FIG. 22 Global Dovitinib Market Revenue, 2018 – 2020 (USD Million) FIG. 23 North America Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million) FIG. 24 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million) FIG. 25 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million) FIG. 26 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million) FIG. 27 Bayer AG: Annual Revenue, 2011 – 2013 (USD Million) FIG. 28 F. Hoffmann-La Roche, Ltd.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 29 GlaxoSmithKline, plc.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 30 Annual Revenue: Novartis AG 2011 – 2013 (USD Million) FIG. 31 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million) List of Tables
TABLE 1 Market Snapshot: Global Kidney Cancer Market TABLE 2 Stages of RCC, According to the U.S. TNM Classification TABLE 3 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 – 2020 (USD Million) TABLE 4 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2020 (USD Million) TABLE 5 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million) Browse All Pharmaceutical Market Research Reports @
Transparency Market Research
12
Kidney Cancer Drugs Market
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse The Market Research Blog : http://researchandreports.wordpress.com/ http://www.transparencymarketresearch.com
Transparency Market Research
13